Preview

Лечащий Врач

Расширенный поиск

Магалдрат как антацид с мультитаргетным воздействием: клинико-фармакологическое эссе

Полный текст:

Аннотация

Алюминия магния гидроксид сульфат 5:10:31:2 (магалдрат) используется как антацид, нейтрализующий избыток соляной кислоты в желудке. При совместном применении с силоксановым полимером симетиконом, магалдрат проявляет минимум побочных эффектов (в частности, не приводит к повышенному газообразованию) на фоне выраженного цитопротекторного действия на слизистую оболочку желудка.

Об авторах

О. А. Громова
ГБОУ ВПО ИвГМА МЗ РФ
Россия


И. Ю. Торшин
ФГБУ ФИЦ ИУ РАН
Россия


В. А. Максимов
ФГБОУ ДПО РМАНПО МЗ РФ
Россия


Список литературы

1. Miederer S. E. Mucous membrane protective effect of long acting antacids. New knowledge on the physiology of the mucin barrier // Fortschr Med. 1993; 111 (6): 25–26.

2. Miederer S. E., Mayershofer R., Loffler A. Magaldrate (100 mmol/d) versus ranitidine (300 mg/d). Healing rates of stomach ulcer in a German double-blind study // Med Klin (Munich). 1986; 81 (5): 162–165.

3. Dammann H. G., Walter T. A., Muller P., Simon B. Are 2 tablets of magaldrate at bedtime effective in the therapy of duodenal ulcer? // Dtsch Med Wochenschr. 1985; 110 (2): 77–79.

4. McCafferty D. F., Woolfson A. D. A comparative assessment of a new antacid formulation based on magaldrate // J Clin Hosp Pharm. 1983; 8 (4): 349–355.

5. Figueroa R. B., Klotz A. P. Clinical-pharmacological evaluation of a new antacid, hydrated magnesium aluminate (riopan) // Curr Ther Res Clin Exp. 1960; 2: 415–421.

6. Baur C., Becker A., Linder R., Schwan T. Neutralizing capacity, pepsin inactivation and binding to bile acids and lysolecithin of the antacid magaldrate (author’s transl) // Arzneimittelforschun. 1981; 31 (3): 504–507.

7. Sulz M. C., Manz M., Grob P., Meier R., Drewe J., Beglinger C. Comparison of two antacid preparations on intragastric acidity — a two-centre open randomised cross-over placebo-controlled trial // Digestion. 2007; 75 (2–3): 69–73. Epub 2007 May.

8. Estruch R., Pedrol E., Castells A., Masanes F., Marrades R. M., Urbano-Marquez A. Prophylaxis of gastrointestinal tract bleeding with magaldrate in patients admitted to a general hospital ward // Scand J Gastroenterol. 1991; 26 (8): 819–826.

9. Bruhn R., Ganote D. P., Lucker P. W. Gastric stimulus response: Euphylline, theophylline, ethylenediamine and Riopan: gastric transmural potential difference (GPD) // Methods Find Exp Clin Pharmacol. 1983; 5 (8): 581–583.

10. Ganote D. P., Bruhn R., Lucker P. W. Comparative measurement of transmural gastric potential difference after administration of Euphyllin solution, theophylline solution, ethylenediamine dihydrochloride solution and Riopan, buffered theophylline // Methods Find Exp Clin Pharmacol. 1982; 4 (8): 601–610.

11. DiJoseph J. F., Borella L. E., Wells C. L., Mir G. N. Mucosal protective activity of activated aluminum complex // Digestion. 1990; 45 (1): 19–25.

12. DiJoseph J. F., Borella L. E., Mir G. N. Activated aluminum complex derived from solubilized antacids exhibits enhanced cytoprotective activity in the rat // Gastroenterology. 1989; 96 (3): 730–735.

13. Miederer S. E., Schmidt C. Lattice structure antacids and antacid mixtures // Z Gastroenterol. 1987; 25 Suppl 3: 130–135.

14. Patel A. V., Santani D. D., Goyal R. K. Antiulcer activity and the mechanism of action of magaldrate in gastric ulceration models of rat // Indian J Physiol Pharmacol. 2000; 44 (3): 350–354.

15. Schmidt C., Baumeister B., Kipnowski J., Miederer S. E., Vetter H. Magaldrate stimulates endogenous prostaglandin E2 synthesis in human gastric mucosa in vitro and in vivo // Hepatogastroenterolo. 1998; 45 (24): 2443–2446.

16. Borella L. E., DiJoseph J. F., Mir G. N. Cytoprotective and antiulcer activities of the antacid magaldrate in the rat // Arzneimittelforschun. 1989; 39 (7): 786–789.

17. Arnold R., Garbe I., Koop H., Monnikes H., Schwarting H. Effect of antacid and H2-receptor blocker treatment on gastric endocrine cells // Scand J Gastroenterol Suppl. 1984; 101: 31–37.

18. Arnold R., Koop H., Nesslinger A., Schwarting H. Effect of drugs with acid-neutralizing and acid-suppressive effect on parietal cell function and on gastrin and somatostatin cell density of the stomach // Z Gastroenterol. 1983; 21 Suppl: 104–110.

19. Zaterka S., Cordeiro F., Lyra L. G., Toletino M. M., Miszputen S. J., Jorge J. L., Silva E. P., Vieira F. E., Modena J. L., Massuda H. K. et al. Very-low dose antacid in treatment of duodenal ulcer. Comparison with cimetidine // Dig Dis Sci. 1991; 36 (10): 1377–1383.

20. Cousar G. D., Gadacz T. R. Comparison of antacids on the binding of bile salts // Arch Surg. 1984; 119 (9): 1018–1020.

21. Al Gohary O. M., Hosny E. A. Effect of antacid magaldrate oral suspension on in-vitro and in-vivo availability of indomethacin in dogs // Pharm Acta Helv. 1997; 72 (2): 81–86.

22. Al Gohary O. M., el Din K., el Tahir H. Formulation of aspirin-magaldrate double-layer tablets: in vitro evaluation and cytoprotective activity in rats // Boll Chim Farm. 1996; 135 (7): 421–428.

23. Peterson C. L., Perry D. L., Masood H., Lin H., White J. L., Hem S. L., Fritsch C., Haeusler F. Characterization of antacid compounds containing both aluminum and magnesium // I. Crystalline powders. Pharm Res. 1993; 10 (7): 998-10-04.

24. Rauch H., Fleischer F., Bohrer H., Jurs G., Wilhelm M., Krier C. Serum aluminium levels of intensive care patients treated with two different antacids for prevention of stress ulceration // Intensive Care Med. 1989; 15 (2): 84–86.

25. Eichhorn M. Aluminum and magnesium burden of dialysis patients using antacids. A comparative study // Fortschr Med. 1989; 107 (23): 502–506.

26. Winterberg B., Bertram H., Rolf N., Roedig M., Kisters K., Remmers S., Spieker C., Zumkley H. Differences in plasma and tissue aluminum concentrations due to different aluminum-containing drugs in patients with renal insufficiency and with normal renal function // J Trace Elem Electrolytes Health Dis. 1987; 1 (2): 69–72.

27. Guterman L. R., Falzone J., Wilson G. E. Jr. Action of hydrochloric acid on aluminum hydroxide-magnesium hydroxide gels and magaldrate: quasi-elastic light scattering studies // J Pharm Sci. 1986; 75 (5): 502–505.

28. Wilson G. E. Jr., Falzone C. J., Johnson R., Lee H. K. Action of hydrochloric acid on aluminum hydroxide-magnesium hydroxide gels and magaldrate: 27 Al NMR and pH-stat studies // J Pharm Sci. 1985; 74 (10): 1075–1077.

29. Brecevic L., Bosan-Kilibarda I., Strajnar F. Mechanism of antifoaming action of simethicone // J Appl Toxicol. 1994; 14 (3): 207–211.

30. Roht U. Simethicone for gastrointestinal gas // Med Lett Drugs Ther. 1996; 38 (977): 57–58.

31. Da Silva K. G., de Andrade C., Sotomaior C. S. Influence of simethicone and fasting on the quality of abdominal ultrasonography in New Zealand White rabbits // Acta Vet Scand. 2017; 59 (1): 48.

32. Aut A. Simethicone for discomfort caused by gastrointestinal gas // Med Lett Drugs Ther. 1975; 17 (19): 80.

33. Darlington H. F. Treatment of the constipation-gas syndrome in geriatric patients: use of a magnesium hydroxide-simethicone emulsion // J Am Geriatr Soc. 1964; 12: 503–507.

34. Yoo I. K., Jeen Y. T., Kang S. H., Lee J. H., Kim S. H., Lee J. M., Choi H. S., Kim E. S., Keum B., Chun H. J., Lee H. S., Kim C. D. Improving of bowel cleansing effect for polyethylene glycol with ascorbic acid using simethicone: A randomized controlled trial // Medicine (Baltimore). 2016; 95 (28): e4163.

35. Ummarino D., Miele E., Martinelli M., Scarpato E., Crocetto F., Sciorio E., Staiano A. Effect of magnesium alginate plus simethicone on gastroesophageal reflux in infants // J Pediatr Gastroenterol Nutr. 2015; 60 (2): 230–235.

36. Coffin B., Bortolloti C., Bourgeois O., Denicourt L. Efficacy of a simethicone, activated charcoal and magnesium oxide combination (Carbosymag®) in functional dyspepsia: results of a general practice-based randomized trial // Clin Res Hepatol Gastroenterol. 2011; 35 (6–7): 494–499.

37. Lecuyer M., Cousin T., Monnot M. N., Coffin B. Efficacy of an activated charcoal-simethicone combination in dyspeptic syndrome: results of a randomized prospective study in general practice // Gastroenterol Clin Biol. 2009; 33 (6–7): 478–484.

38. Ansorg R., von Recklinghausen G., Heintschel von Heinegg E. Susceptibility of Helicobacter pylori to simethicone and other non-antibiotic drugs // J Antimicrob Chemother. 1996; 37 (1): 45–52.


Рецензия

Для цитирования:


Громова О.А., Торшин И.Ю., Максимов В.А. Магалдрат как антацид с мультитаргетным воздействием: клинико-фармакологическое эссе. Лечащий Врач. 2018;(2):67.

For citation:


Gromova O.A., Torshin I.Yu., Maksimov V.A. Magaldrate as an antiacid with multi-target effect: clinical-pharmacological essay. Lechaschi Vrach. 2018;(2):67. (In Russ.)

Просмотров: 62


Creative Commons License
Контент доступен под лицензией Attribution-NonCommercial-NoDerivatives 4.0 International.


ISSN 1560-5175 (Print)
ISSN 2687-1181 (Online)